SB 258719 is primarily used in research settings to study its effects on serotonin receptors, particularly the 5-HT7 receptor subtype. It acts as a selective antagonist, helping scientists understand the role of these receptors in various physiological and pathological processes. This compound has been instrumental in exploring the potential therapeutic applications of 5-HT7 receptor modulation, particularly in neurological and psychiatric disorders such as depression, anxiety, and schizophrenia. Additionally, it aids in investigating the receptor's involvement in circadian rhythm regulation and cognitive functions. Its use in preclinical studies contributes to the development of novel drugs targeting serotonin-related pathways.